2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2069

High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2070

Urinary Biomarker Based “a-RAIL”� Study in Adults with Lupus Nephritis
Abstract Number: 2071

Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Abstract Number: 2072

Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus
Abstract Number: 2073

Mitochondrial ROS Is a Novel Regulator of Sting-Mediated Type I IFN Production By Governing Extrusion of Oxidized Mitochondrial DNA upon Neutrophil Extracellular Trap Formation.
Abstract Number: 2074

Dominant Chilblain Lupus Due to an Activating Mutation of Sting – Suppression of Constitutive Type I Interferon Activation By JAK Inhibition
Abstract Number: 2075

A Unique Naturally-Occurring Regulatory T Cell Subset Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 2076

Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis
Abstract Number: 2077

Does Dysbiosis within the Intestinal Microbiome Contribute to SLE Pathogenesis?
Abstract Number: 2078

Reserve Capacity: Explaining the Link Between Socioeconomic Status and Depression/Anxiety Among Patients with Systemic Lupus Erythematosus
Abstract Number: 2079

Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression
Abstract Number: 2080

Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers
Abstract Number: 2081

The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Abstract Number: 2082

Evaluations of Social Support Are Associated with Well-Being Outcomes in Women with Systemic Lupus Erythematosus (SLE)
Abstract Number: 2083

Predictors of Health Perceptions Among Women with Lupus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].